The large prostate cancer study STHLM2, conducted by researchers at the Karolinska Institute, has initiated collaboration with Uppsala based bio-diagnostic company Biovica to test whether thymidine kinase is an interesting biomarker for prostate cancer.
Swedish bio-diagnostic company Biovica has signed a three-year, SEK 2.2 million contract with Polish distributor Genoxa. The agreement gives Genoxa the exclusive right to use, sell, distribute and market DiviTum™, Biovicas unique assay for measuring cell-division, in Poland. All together this gives 38 million people access to the most high-tech, scientific cutting-edge assay for measuring [...]
New scientific data published: DiviTum™ delivers valuable new knowledge in patients with lymphatic disease Dr N.K Parilova and colleagues at P-A Herzen, Moscow Oncology Research Institute has studied levels of Thymidine Kinase (TK) measured with DiviTum™ in patients with lymphatic diseases. DiviTum™ demonstrated high diagnostic sensitivity for both lymphatic disease and cancer (Non-Hodgkin’s lymphomas). DiviTum™ [...]
DiviTum™ scientific results presented at the European Heamatology Conference Two abstracts from the University Hospital in Olomouc, Czech Republic presented at the European Heamatology Conference in Amsterdam, June 14-17, demonstrated the value of using DiviTum™ as a prognostic biomarker and it’s unprecedented sensitivity. Dr Prochazka and research colleagues demonstrated that DiviTum™ extends the detection range [...]
Biovica received an award at the 23rd Nordic Congress in Clinical Chemistry in Reykjavik, Iceland, 12-15 June 2012. The award was given for the poster entitled ”Total body cell proliferation rate measured by serum mediated thymidine incorporation – a novel clinical chemistry biomarker”. –This proves that our work with developing DiviTum™ as a most [...]